Abstract STAT6, located on chromosome 12, encodes a transcription factor whose SH2 domain is central to its activation. While classically a Th2 mediator, aberrant STAT6 activation is observed in diverse malignancies. This review focuses on the molecular and functional landscape of STAT6, primarily in cancer and tumor i...
Hiba Narvel, D. Nishizaki, S. Kato et al.· ImmunoTargets and Therapy· 0 citations
Cancer therapeutics has been revolutionized by the introduction of molecularly targeted therapies and immune checkpoint inhibitors (ICIs). The paradigm of neoadjuvant therapy is commonly employed across multiple solid tumors, exhibiting significant clinical benefit as exemplified with ICIs in melanoma and non-small-cel...
D. Nishizaki, R. N. Eskander· Hematology/Oncology Clinics...· 0 citations
Metastatic pancreatic cancer (PC) has a dismal 5-year survival rate of 2% due to limited chemotherapy, lack of immunotherapy options, and high drug resistance. The tumor-immune microenvironment (TIME) in PC, marked by dense desmoplasia, inactive anti-cancer T-cells, and immunosuppressive regulatory T-cells (Tregs...
In Hwan Park, G. Botta, Shawn A. Abeynaike et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of approximately 13% and remains largely resistant to immunotherapy because its dense fibrotic stroma restricts drug penetration, and its immunosuppressive tumor microenvironment (TME) limits anti-tumor immunity. Novel strategies are urgently needed t...
Shawn A. Abeynaike, In Hwan Park, Ashley Martinez et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.